ストックスクリーナーアプリを入手
6.74
7.67%
0.48
アフターアワーズ：
6.81
0.07
+1.04%
Foghorn Therapeutics Inc (FHTX) 最新ニュース
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 By Investing.com - Investing.com Canada
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 - Investing.com
Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy - Yahoo Finance
Foghorn Therapeutics Inc (NASDAQ: FHTX) Stock Price, News & Analysis - Kalkine
News Flash: Analysts Just Made A Huge Upgrade To Their Foghorn Therapeutics Inc. (NASDAQ:FHTX) Forecasts - simplywall.st
Enterprise value to EBIT forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
HC Wainwright Issues Negative Outlook for FHTX Earnings - MarketBeat
Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade - Yahoo Finance
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Wall Street Zen Upgrades Foghorn Therapeutics (NASDAQ:FHTX) to Hold - MarketBeat
Foghorn Therapeutics Reports Q2 Results and Pipeline Progress - The Globe and Mail
BTIG Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Discipline and Rules-Based Execution in FHTX Response - Stock Traders Daily
Foghorn Therapeutics (NASDAQ:FHTX) Issues Earnings Results, Beats Estimates By $0.13 EPS - MarketBeat
Foghorn Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Foghorn Therapeutics advances FHD-909 with Lilly and launches oral immunology program in Q2 update - tradersunion.com
Foghorn Therapeutics Inc. 2026: Revenue $16.07M, EPS ($0.1) — 10-Q Summary - TradingView
Lilly deal lifts Foghorn Therapeutics (Nasdaq: FHTX) Q2 2026 revenue and cuts loss - Stock Titan
Foghorn’s lung cancer trial advances; IND targeted for 2027 - stocktitan.net
Foghorn Therapeutics (FHTX) Jumps 5.4% as Biotech Stock Approaches Key Resistance at $5.10Combination Correction - dars.gov.et
Foghorn Therapeutics (FHTX) Rises 1.77% as Shares Hold Above Key Support at $4.38Dividend Arbitrage - dars.gov.et
Foghorn Therapeutics (FHTX) Slides 4.4% to $4.53, Approaching Key Support LevelRounding Bottom - dars.gov.et
Foghorn Therapeutics Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
Foghorn Therapeutics Inc. (FHTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Foghorn Therapeutics (FHTX) Expected to Release Earnings on Tuesday - MarketBeat
Foghorn Therapeutics Inc. (FHTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
FHTX|Foghorn Therapeutics Inc.|Price:4.880|Chg%:+0.020 - TradingKey
Price to sales forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
Enterprise value to revenue forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
Foghorn Therapeutics Inc. (FHTX) Cash Flow - TradingKey
Foghorn Therapeutics Inc. (FHTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
FHTX|Foghorn Therapeutics Inc.|Price:4.850|Chg%:-0.220 - TradingKey
TradingKey - TradingKey
(FHTX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
FHTXFoghorn Therapeutics Inc Options - Finviz
FHTX SEC FilingsFoghorn Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains? - Yahoo Finance
We're Keeping An Eye On Foghorn Therapeutics' (NASDAQ:FHTX) Cash Burn Rate - Moomoo
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director - Investing News Network
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director - GlobeNewswire Inc.
Foghorn Therapeutics Inc.(NasdaqGM: FHTX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from Russell 3000E Value Benchmark - marketscreener.com
Foghorn Therapeutics (FHTX) Rises 4.71% as Biotech Stock Tests Key Resistance at $4.43Daily Profile - dars.gov.et
Soft Tissue Sarcoma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | OncoTherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma Holdings - Barchart.com
Foghorn Therapeutics, Inc. Actuals & Estimates (NASDAQ:FHTX) - TradingView
Form 4 Foghorn Therapeutics Inc For: 25 June By Investing.com - Investing.com Australia
FHTX Forecast — Price Target — Prediction for 2027 - TradingView
Director at Foghorn Therapeutics (FHTX) receives 28,000 stock options - Stock Titan
Foghorn Therapeutics (FHTX) director granted 28,000 stock options at $4.08 strike - Stock Titan
Foghorn Therapeutics (FHTX) director receives stock options for 28,000 shares - Stock Titan
Director at Foghorn (NASDAQ: FHTX) receives 28,000 stock options grant - Stock Titan
Director Michael Mendelsohn gets 28,000 Foghorn (FHTX) stock options at $4.08 - Stock Titan
Director Ian F. Smith receives 28,000 Foghorn Therapeutics (FHTX) stock options - Stock Titan
Foghorn Therapeutics (FHTX) director Simba Gill granted 28,000 stock options - Stock Titan
Foghorn Therapeutics (FHTX) director Lynne Parshall awarded 28,000 stock options - Stock Titan
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):